REFERENCES
[1]. RodloffA , GoldsteinE , TorresA .Two decadesofimipenem
therapy.J Antimi- crob Chemother 2006;58:916–29.
[2]. Joseph J, Rodvold KA. The role of carbapenems in the treatment
of severe nosocomial respiratory tract infections. Expert Opin
Pharmacother 2008;9(4): 561-575.
[3] Tieu JD, William RS 2nd, Skrepnek GH, et al. Pharmacokinetic
changes of antibiotic, antiviral, antituberculosis and antifungal agents
during extracorporeal membrane oxygenation in critically ill adult
patients. J Clin Pharm Ther 2017;42(6):661-671
[4]. Pajot O, Burdet C, Couffignal C, et al. Impact of imipenem and
amikacin pharmacokinetic/pharmacodynamic parameters on microbiological
outcome of Gram-negative bacilli ventilator-associated pneumonia. J
Antimicrob Chemother 2015;70(5): 1487-1494.
[5]. Seo YB, Lee J, Kim YK, et al. Randomized controlled trial of
piperacillin-tazobactam, cefepime and ertapenem for the treatment of
urinary tract infection caused by extended-spectrum
beta-lactamase-producing Escherichia coli. BMC Infect Dis 2017;17(1):
404.
[6]. A. Bricheux, L. Lenggenhager, S. Hughes, A. Karmime, P.
Lescuyer, A. Therapeutic drug monitoring of imipenem and the incidence
of toxicity and failure in hospitalized patients: a retrospective cohort
study. Clin Microbiol Infect 2019;25(3):383.e1-383.e4.
[7]. McKinnon P, Paladino JA, Schentag JJ. Evaluation of area under
the inhibitory curve (AUIC) and time above the minimum inhibitory
concentration (T>MIC) as predictors of outcome for cefepime
and ceftazidime in serious bacterial infections. Int J Antimicrob Agents
2008;31(4): 345-351.
[8]. Li C, Du X, Kuti JL, et al. Clinical pharmacodynamics of
meropenem in patients with lower respiratory tract infections.
Antimicrob Agents Chemother 2007;51(5): 1725-30.
[9]. Lipš M, Siller M, Strojil J, et al. Pharmacokinetics of
imipenem in critically ill patients during empirical treatment of
nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. Int J
Antimicrob Agents 2014;44(4): 358-362.
[10].Yoshida M, Takasu Y, Shimizu K, et al, Prediction of the
stability of imipenem in intravenous mixtures. Chem Pharm Bull (Tokyo)
2013;61(1): 1-7.
[11].Pratik Bhagunde, Zufei Zhang, Fred Racine, Donna Carr, Jin Wu,
Katherine Young. A Translational Pharmacokinetic/Pharmacodynamic Model
to Characterize Bacterial Kill in the Presence of Imipenem-Relebactam.
Int J Infect Dis 2019;12(89):55-61.
[12].Sanwang Li, Feifan Xie. Population pharmacokinetics and
simulations of imipenem in critically ill patients undergoing continuous
renal replacement therapy. International Journal of Antimicrobial Agents
2019;53(1):98-105.
[13]. Ide T, Takesue Y, Ikawa K, et al. Population
pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with
and without continuous renal replacement therapy. Int J Antimicrob
Agents 2018;51(5):745-751.
[14]. Couffignal C, Pajot O, Laouénan C, et al. Population
pharmacokinetics of imipenem in critically ill patients with suspected
ventilator-associated pneumonia and evaluation of dosage regimens. Br J
Clin Pharmacol 2015;78(5):1022-1034.
[15]. Galani I, Nafplioti K, Chatzikonstantinou M, et al. In vitro
evaluation of double-carbapenem combinations against OXA-48-producing
Klebsiella pneumoniae isolates using time-kill studies. J Med Microbiol
2018;3(67):662-668.
[16]. Lee W, Cai Y, Lim TP, Teo J, Chua SC, Kwa AL. In vitro
pharmacodynamics and PK/PD in animals. Adv Exp Med Biol
2019;1145:105–116.
[17]. Wu J, Racine F, Wismer MK, Young K, Carr DM, Xiao JC, et al.
Exploring the pharmacokinetic/pharmacodynamic relationship of relebactam
(MK-7655) in combination with imipenem in a hollow-fiber infection
model. Antimicrob Agents Chemother 2018;62(5):e02323.
[18]. Motsch J, de Oliveira CM, Stus V, Köksal I, Lyulko O, Boucher
HW, et al. RESTORE-IMI 1: a multicenter, randomized, doubleblind trial
comparing efficacy and safety of imipenem/relebactam vs colistin plus
omipenem in patients with imipenem-nonsusceptible bacterial infections.
Clin Infect Dis 2020;70(9):1799-1808.
[19]. Dulhunty JM, Roberts JA, Davis JS, et al. A Multicenter
Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in
Severe Sepsis. Am J Respir Crit Care Med 2015;192(11):1298-305.
[20] Sutep Jaruratanasirikul, Veerapong Vattanavanit, Maseetoh
Samaeng, Monchana Nawakitrangsan, Somchai Sriwiriyajan. Pharmacokinetics
of Imipenem in Critically Ill Patients with Life‑threatening Severe
Infections During Support with Extracorporeal Membrane Oxygenation. Clin
Drug Investig 2019;39(8):787-798.
[21]. Tambo M, Taguchi S, Nakamura Y, Okegawa T, Fukuhara H.
Presepsin and procalcitonin as predictors of sepsis based on the new
Sepsis-3 definitions in obstructive acute pyelonephritis. BMC Urol
2020;20(1):23.
[22]. Charles PE, Tinel C, Barbar S, et al. Procalcitonin kinetics
within the first days of sepsis: relationship with the appropriateness
of antibiotic therapy and the outcome. Crit Care 2009;13(2):1-11.
[23]. Hohn A, Heising B, Schütte JK, et al. Procalcitonin-guided
antibiotic treatment in critically ill patients. Langenbecks Arch Surg
2017;402(1): 1-13.
[24]. Smith SE, Muir J, Kalabalik-Hoganson J. Procalcitonin in
special patient populations: Guidance for antimicrobial therapy. Am J
Health Syst Pharm 2020;77(10):745-758.
Table 1. Patients’ basic information of different groups